These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia. Gu J; Kuznik A; Quon P; Chauhan A; Sravya TS; Raal FJ Eur J Prev Cardiol; 2023 Nov; 30(17):1874-1880. PubMed ID: 37314419 [TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries. Arca M; Celant S; Olimpieri PP; Colatrella A; Tomassini L; D'Erasmo L; Averna M; Zambon A; Catapano AL; Russo P J Am Heart Assoc; 2023 Nov; 12(21):e026550. PubMed ID: 37850449 [TBL] [Abstract][Full Text] [Related]
5. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study. Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890 [TBL] [Abstract][Full Text] [Related]
6. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Raal FJ; Hegele RA; Ruzza A; López JAG; Bhatia AK; Wu J; Wang H; Gaudet D; Wiegman A; Wang J; Santos RD Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1156-1164. PubMed ID: 38545781 [TBL] [Abstract][Full Text] [Related]
7. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study. Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335 [TBL] [Abstract][Full Text] [Related]
8. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry. D'Erasmo L; Bini S; Casula M; Gazzotti M; Bertolini S; Calandra S; Tarugi P; Averna M; Iannuzzo G; Fortunato G; Catapano AL; Arca M; Eur J Prev Cardiol; 2024 Jun; 31(8):1038-1047. PubMed ID: 38374534 [TBL] [Abstract][Full Text] [Related]
9. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis. Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572 [TBL] [Abstract][Full Text] [Related]
10. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study. Alonso R; Arroyo-Olivares R; Muñiz-Grijalvo O; Díaz-Díaz JL; Muñoz-Torrero JS; Romero MJ; de Andrés R; Zambón D; Mañas MD; Fuentes-Jiménez F; Aguado R; Alvarez-Baños P; Arrieta F; Gonzalez-Bustos P; Cepeda J; Martin-Ordiales M; Mosquera D; Michan A; de Isla LP; Argueso R; Mata P Eur J Prev Cardiol; 2023 Mar; 30(4):320-328. PubMed ID: 36416136 [TBL] [Abstract][Full Text] [Related]
11. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study. Alonso R; Arroyo-Olivares R; Díaz-Díaz JL; Fuentes-Jiménez F; Arrieta F; de Andrés R; Gonzalez-Bustos P; Argueso R; Martin-Ordiales M; Martinez-Faedo C; Illán F; Saenz P; Donate JM; Sanchez Muñoz-Torrero JF; Martinez-Hervas S; Mata P Atherosclerosis; 2024 Jun; 393():117516. PubMed ID: 38523000 [TBL] [Abstract][Full Text] [Related]
12. Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). Gaudet D; Durst R; Lepor N; Bakker-Arkema R; Bisgaier C; Masson L; Golden L; Kastelein JJ; Hegele RA; Stein E Am J Cardiol; 2019 Dec; 124(12):1876-1880. PubMed ID: 31685212 [TBL] [Abstract][Full Text] [Related]
13. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068 [TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
15. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335 [TBL] [Abstract][Full Text] [Related]
16. PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials. Benhuri B; Ueyama H; Takagi H; Briasoulis A; Kuno T Curr Vasc Pharmacol; 2021; 19(4):390-397. PubMed ID: 32767943 [TBL] [Abstract][Full Text] [Related]
17. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604 [TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study. Jensen JS; Weeke PE; Bang LE; Høfsten DE; Ripa MS; Schjerning AM; Theilade JE; Køber LV; Gislason GH; Pallisgaard J BMJ Open; 2019 Apr; 9(4):e022702. PubMed ID: 30940751 [TBL] [Abstract][Full Text] [Related]
19. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial. Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394 [TBL] [Abstract][Full Text] [Related]
20. [Consensus statement of professional associations on prescribing of PCSK9-inhibitors]. Češka R; Táborský M; Vrablík M Vnitr Lek; 2019; 64(12):1131-1136. PubMed ID: 30704246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]